Google Scholar: citas
Usefulness of Antigen Carbohydrate 125 and N-Terminal Pro-B-Type Natriuretic Peptide for Assessing Congestion in Chronic Heart Failure : Insights from the CARDIOREN Registry
Nuñez, J. (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Llacer, P. (Hospital Universitario Ramon y Cajal)
Zegrí-Reiriz, Isabel (Institut de Recerca Sant Pau)
De la Espriella, Rafael (Hospital Clínico Universitario de Valencia)
Mendez, A. (Hospital Universitari Vall d'Hebron)
Górriz, Jose Luis (Hospital Clínico Universitario de Valencia)
Cobo Marcos, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Gayán Ordás, J. (Institut de Recerca Biomedica (IRB))
Bascompte Claret, R. (Institut de Recerca Biomedica (IRB))
Fort, A. (Hospital Universitario Josep Trueta)
Rubio-Gracia, J. (Hospital Universitario Lozano Blesa)
Blazquez-Bermejo, Z. (Hospital General Universitario Gregorio Marañón)
Ponz, I. (Hospital Universitario la Paz)
Rodriguez Chaverri, A. (Hospital Universitario la Paz)
Caravaca Perez, Pedro (Hospital Clínic i Provincial de Barcelona)
Recio Mayoral, A. (Hospital Universitario Virgen Macarena)
Jiménez Rubio, C. (IBIMA-Plataforma BIONAND)
Pomares, Antonia (Institut de Recerca Sant Pau)
José Soler, M. (Hospital Universitari Vall d'Hebron)
Fluviá, P. (Hospital Universitario Josep Trueta)
García Magallón, B. (Hospital Universitario Puerta de HIerro)
Manzano, L. (Hospital Universitario Ramon y Cajal)
Husain-Syed, F. (San Bortolo Hospital)

Fecha: 2024
Resumen: Introduction: A comprehensive assessment of congestion, including circulating biomarkers, is recommended in patients with acute heart failure. The circulating biomarkers natriuretic peptides (NPs) and carbohydrate antigen-125 (CA125) could be useful for congestion assessment in ambulatory chronic heart failure (CHF), but there is only limited information about their applicability in this context. Therefore, this study aimed to examine the association of plasma CA125 and NP levels with clinical and ultrasound congestion parameters in CHF. Methods: This is a cross-sectional substudy of the Cardioren Spanish Registry, which enrolled 1,107 patients with CHF from 13 tertiary hospitals in Spain between October 2021 and February 2022. Through ambulatory visits, we performed a comprehensive assessment of congestion-related parameters, including clinical variables (orthopnea, peripheral edema, and jugular engorgement, represented by the composite congestion score [CCS]), echocardiography variables (lung B-lines and inferior vena cava [IVC] diameter), and circulating biomarkers (CA125 and NPs). The association of the NP and CA125 levels with the clinical and echocardiographic congestion parameters was examined by multiple linear and logistic regression analyses. Results: This substudy included 802 patients for whom all the biomarker parameters were available {median age, 74 (interquartile range [IQR], 63-81) years; 65% male}. The proportion of patients with left ventricular ejection fraction ≥50% and estimated glomerular filtration rate <60 was 34% and 58%, respectively. The median CCS was 0 (IQR: 0-1), with 45% of the sample exhibiting a median CCS of ≥1. The jugular engorgement, peripheral edema, and orthopnea rates were 32%, 21%, and 21%, respectively. A total of 35% of patients who underwent ultrasound examination showed lung B-lines, and the median IVC diameter was 16 mm. The median CA125 and NTproBNP levels were 14 U/mL (IQR: 9-28) and 1,382 pg/mL (IQR: 563-3,219), respectively. Multivariate analysis showed that higher CA125 levels were independently associated with higher odds of peripheral edema (p = 0. 023) and lung B-lines (p < 0. 001). Further, NTproBNP was positively associated with jugular engorgement (p < 0. 001), orthopnea (p = 0. 034), and enlarged IVC diameter (p = 0. 031). Conclusions: Clinical signs of congestion are frequent in CHF. In the ambulatory setting, NTproBNP was associated with parameters linked to intravascular congestion such as orthopnea, jugular engorgement, and IVC diameter, whereas CA125 was associated with extravascular volume overload parameters (peripheral edema and lung B-lines).
Derechos: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. Creative Commons
Lengua: Anglès
Documento: Article ; recerca ; Versió publicada
Materia: Carbohydrate antigen-125 ; Chronic heart failure ; Congestion ; Fluid overload ; Natriuretic peptides ; Ultrasound
Publicado en: CardioRenal Medicine, Vol. 14, Num. 1 (May 2024) , p. 543-555, ISSN 1664-5502

DOI: 10.1159/000541324
PMID: 39236691


13 p, 802.3 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados

 Registro creado el 2026-01-15, última modificación el 2026-01-16



   Favorit i Compartir